Date | Compound | Laboratory | Indication | Type of Information |
---|---|---|---|---|
2012-05-23 | 2-Allyl-1-[6-(1-hydroxy-1-methylethyl)pyridin-2-yl]-6-{[4-(4-methylpiperazin-1-yl)phenyl]amino}-1,2-dihydro-3H-pyrazolo[3,4-d]pyrimidin-3-one | Merck&Co (USA) | ovarian cancer | |
2012-05-24 | regorafenib | Bayer Healthcare (Germany) | treatment of patients with metastatic colorectal cancer (mCRC) who have been previously treated with currently available therapies (including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapy, an anti-VEGF therapy, and if KRAS wild type, an anti-EGFR therapy). | Granting of a Market Authorisation in the EU |
2015-02-09 | zonisamide | Eisai (Japan) | partial seizures (with or without secondary generalisation) in adults with newly diagnosed epilepsy. |
Product launch |
2014-11-21 | perampanel | Eisai (Japan) | adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in patients with epilepsy aged 12 years and older |
Product launch |
2014-01-24 | linagliptin/metformin hydrochloride | Boehringer Ingelheim (Germany) Eli Lilly (USA) | type 2 diabetes mellitus in adults |
Granting of a Market Authorisation in the EU |
2012-05-29 | catridecacog | Novo Nordisk (Denmark) | long term prophylactic treatment of bleeding in patients 6 years and above with congenital factor XIII A-subunit deficiency |
Granting of a patent |
2014-07-21 | acyclovir Lauriad™ | BioAlliance Pharma (France) | recurrent orofacial herpes | Product launch |
2013-09-23 | eltrombopag | GSK (UK) | increase of platelet counts in patients with chronic hepatitis C virus infection and low platelets (thrombocytopenia) |
Granting of a Market Authorisation in the EU |
2012-06-05 | bevacizumab | Roche (Switzerland) | front-line (first-line following surgery) treatment for women with advanced ovarian cancer | Granting of a Market Authorisation in the EU |
2012-06-05 | TB-403 (RG7334) | BioInvent (Sweden) Thrombogenics (Belgium) | ||
2012-06-04 | tesamorelin | Theratechnologies (Canada) Sanofi (France) | treatment of excess abdominal fat in adult HIV-infected patients with lipodystrophy | Submission of an NDA |
2012-06-11 | gabapentin enacarbil | GSK (UK) Xenoport (USA) | postherpetic neuralgia |
Granting of a Market Authorisation in the US |
2014-11-14 | alemtuzumab | Genzyme (USA - MA), a Sanofi company (France) | relapsing remitting multiple sclerosis (RRMS) |
Granting of a Market Authorisation in the US |
2012-06-18 | KBSA301 - human monoclonal antibody against severe Staphylococcus aureus pneumonia | Kenta Biotech (Switzerland) | severe pneumonia caused by Staphylococcus aureus (S. aureus) | |
2012-06-21 | 1-[(2-Chloro-4-methoxyphenoxy)methyl]-4-[(2,6-dichlorophenoxy) methyl]benzene | ProPhase Development (UK) | prevention of poliomyelitis in patients with immunodeficiencies deemed at risk | |
2012-06-21 | metreleptin (analog of the human hormone leptin) | Aptiv Solutions (UK) | Barraquer-Simons syndrome | Granting of the orphan status in the EU |
2012-06-21 | metreleptin (analog of the human hormone leptin) | Aptiv Solutions (UK) | Berardinelli-Seip syndrome | Granting of the orphan status in the EU |
2012-06-21 | metreleptin (analog of the human hormone leptin) | BMS (USA) AstraZeneca (UK) Aptiv Solutions (UK) | congenital generalized or acquired generalized lipodystrophy | Granting of a Market Authorisation in the US |
2012-06-21 | metreleptin (analog of the human hormone leptin) | Aptiv Solutions (UK) | Lawrence syndrome | Granting of the orphan status in the EU |
2017-05-16 | (2S)-2-{[(2R)-2-[({[3,3-dibutyl-7-(methylthio)-1,1-dioxido-5-phenyl-2,3,4,5-tetrahydro-1,2,5-benzothiadiazepin-8-yl]oxy}acetyl)amino]-2-(4-hydroxyphenyl)acetyl]amino}butanoic acid | Albireo Pharmaceuticals (USA - MA) Albireo (Sweden) | progressive familial intrahepatic cholestasis | Granting of a patent |
© 2024 Biopharmanalyses - Powered by Samacom+